SEC Form 4 · accession 0001237899-17-000031
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Larosa
Officer — SVP General Counsel and Secret
Period of report
Dec 12, 2017
Accepted (ET)
Dec 13, 2017 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $378.98 | Dec 12, 2017 | A | 23,337 | A | — | Dec 12, 2027 | Common Stock | 23,337 | 23,337 | D |
Explanation of responses
- F1The stock option award vests in four equal annual installments, commencing one year after the date of grant.